Dual-Loading Tumor Information: Personalized Dendritic Cell Vaccine Enters Trial for Advanced Melanoma

Advanced melanoma has had more treatment options since the advent of immune checkpoint inhibitors, but once the tumor continues to progress after anti-PD-1 treatment, the next step is often more challenging. HonorHealth Research Institute has now joined a multicenter clinical trial of DOC1021, a vaccine made from patients’ own immune cells, to explore whether it can enable the immune system to recognize and attack the tumor again.

The Phase 1/2 study, called DOC-RM, is enrolling patients with unresectable or metastatic melanoma whose disease has progressed after at least one systemic therapy; prior treatment must include an anti-PD-1 drug. The trial will first assess treatment tolerability in a small safety cohort, followed by an expansion phase to observe tumor responses.

The manufacturing process for DOC1021 is highly personalized. The research team obtains dendritic cells from each patient and “dual-loads” them with tumor lysate prepared from a fresh tumor specimen and amplified tumor-derived mRNA. Dendritic cells are naturally responsible for presenting antigens to T cells; the researchers hope that simultaneously providing a broad range of antigenic cues represented by tumor proteins and RNA will reduce the possibility that a highly heterogeneous tumor will escape a treatment targeting only a single marker.

Under the trial design, DOC1021 is injected near lymph nodes associated with active tumors, and patients also receive four once-weekly doses of pegylated interferon alfa-2a. The overall treatment includes two courses of DOC1021, with an optional additional booster about six months later. The company says that myeloablative chemotherapy is not required before administration and that high-dose IL-2 is not used, although these practical advantages must still be validated in actual clinical implementation.

The study will not only record adverse events but will also assess objective tumor responses, survival, circulating tumor DNA, immune biomarkers, and quality of life. These measures will help determine whether the vaccine truly changes the course of the tumor and which patients may develop an immune response, rather than merely confirming whether the product can be successfully manufactured and administered.

The currently available public information describes the trial’s launch and design; no efficacy results in patients with melanoma are yet available. The evidence supporting progression to human studies comes mainly from preclinical models, including B16F10 melanoma. DOC1021 data released by the company in other cancer types also cannot be directly extrapolated to melanoma that has progressed after anti-PD-1 treatment. The tumor specimens, time, and quality consistency required for personalized manufacturing will likewise be important tests of whether this therapeutic approach can advance beyond early-stage trials.